4DMedical Ltd (AU:4DX)
ASX:4DX
Want to see AU:4DX full AI Analyst Report?
4DX Stock Chart & Stats
AU$5.84
<AU$0.01(1.02%)
At close: 4:00 PM EST
AU$5.84
<AU$0.01(1.02%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$7.55
Previous CloseN/A
Volume497.15K
Average Volume (3M)10.77M
Market Cap
AU$2.48B
Enterprise ValueAU$2.34B
Total Cash (Recent Filing)AU$56.76M
Total Debt (Recent Filing)AU$6.42M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 27, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,004,940
10 Day Avg. Volume5,850,211
30 Day Avg. Volume10,774,582
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.80
Price to Sales (P/S)8.81
P/FCF Ratio-1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$4.45Price Target Upside-23.80% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)AU$9.00M
Bulls Say, Bears Say
Bulls Say
Proprietary XV Technology4DMedical’s XV imaging platform is a differentiated, clinically focused product offering that creates functional lung maps from CT imaging. That proprietary technology and software positioning supports durable competitive advantage in respiratory imaging, aiding clinical adoption, recurring service opportunities and long-term product-led revenue.
Conservative LeverageA low debt-to-equity ratio and stable equity ratio provide balance-sheet resilience, giving the company financial flexibility to fund continued product development and commercialization. This conservative leverage reduces refinancing risk over the next several quarters and supports survival through extended development cycles.
High Gross Profit MarginA high gross margin indicates attractive unit economics for the core XV software and imaging services, implying scalability if fixed costs are managed. Strong gross margins support eventual operating leverage as volumes grow and can underpin sustainable profitability once revenue trends reverse and operating expenses normalize.
Bears Say
Declining RevenueA continued revenue contraction undermines scale and slows the path to positive operating leverage. For a medtech software business, falling revenue suggests slower clinical adoption or commercial execution issues, making it harder to absorb fixed R&D and sales costs and delaying sustainable profitability over the medium term.
Negative Cash FlowSustained negative operating and free cash flows indicate ongoing cash burn that pressures liquidity and operational flexibility. Over 2–6 months this can force fundraising or cost cuts, limiting investment in commercialization and product development and increasing dilution or covenant risk if external financing is required.
Persistent Losses & Negative ROEOngoing net losses and negative ROE signal that current business economics do not yet generate shareholder returns. This structural profitability shortfall risks recurring capital raises, constrains strategic initiatives, and raises questions about the timeline to break-even absent clear revenue inflection or material margin improvements.
4DMedical Ltd News
4DX FAQ
What was 4DMedical Ltd’s price range in the past 12 months?
4DMedical Ltd lowest share price was AU$0.23 and its highest was AU$7.55 in the past 12 months.
What is 4DMedical Ltd’s market cap?
4DMedical Ltd’s market cap is AU$2.48B.
When is 4DMedical Ltd’s upcoming earnings report date?
4DMedical Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 100 days.
How were 4DMedical Ltd’s earnings last quarter?
4DMedical Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.259 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.223.
Is 4DMedical Ltd overvalued?
According to Wall Street analysts 4DMedical Ltd’s price is currently Overvalued.
Does 4DMedical Ltd pay dividends?
4DMedical Ltd does not currently pay dividends.
What is 4DMedical Ltd’s EPS estimate?
4DMedical Ltd’s EPS estimate is -0.04.
How many shares outstanding does 4DMedical Ltd have?
4DMedical Ltd has 595,004,940 shares outstanding.
What happened to 4DMedical Ltd’s price movement after its last earnings report?
4DMedical Ltd reported an EPS of -AU$0.259 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went up 7.527%.
Which hedge fund is a major shareholder of 4DMedical Ltd?
Currently, no hedge funds are holding shares in AU:4DX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4DMedical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$4.45 (-23.80% Downside)
AU$4.45 (-23.80% Downside)
Blogger Sentiment
Bullish
AU:4DX Sentiment 93%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.21%
12-Months-Change
Fundamentals
Return on Equity
-890.76%
Trailing 12-Months
Asset Growth
36.79%
Trailing 12-Months
Company Description
4DMedical Ltd
4DMedical Limited operates as a medical technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging technology. The company also offers software as a service delivery model; XV lung ventilation analysis software; Permetium, a preclinical imaging system which quantify regional changes in pulmonary function; and AccuVent 200, a small animal ventilator. The company was incorporated in 2012 and is based in Carlton, Australia.
4DX Stock 12 Month Forecast
Average Price Target
AU$4.45
▼(-23.80% Downside)
Technical Analysis
Impedimed Limited
―
Cyclopharm Limited
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
Options Prices
Currently, No data available
---